Generalized Anxiety Disorder
Severe, ongoing anxiety that interferes with daily activities.
Generalized anxiety disorder can occur at any age.
The condition has symptoms similar to panic disorder, obsessive-compulsive disorder, and other types of anxiety. These symptoms include constant worry, restlessness, and trouble with concentration.
Treatment may include counseling and medications, such as antidepressants.
Cluster Number:
Wiki Number:
Diagnosis: W090
US Patients: Generalized Anxiety Disorder
World Patients: 3-5%
Sex Ratio:
Age Onset: M;W2
Brain Area: Age 31
Symptoms: more amygdala and medial pfc activities; hippocampus, insula & orbitofrontal cortex
Progression: excessive, uncotnrollable and often irrational worry about ev ents or activities. frequent autonomic arousal
Causes: 60% develop depression
Medications: may be hereditary (40%)or genetic + environment-actual experiences
Therapies: norepinephrine inhibitors, antianxiety drugs, (many, many drug options-but many with possibly fatal side effects)
CBT-less catastrophizing, and other CBT orientations, relaxation, mindfulness, physical exercise
Youtube Video: What is Generalized Anxiety Disorder?
Amazon or Library Book: Overcoming Generalized Anxiety Disorder
Support Group: nami.org; 800-950-6264 (National Alliance on Mental Illness)
Contact you local Social Security office for possible Disability Benefits through their Disability Determination Services,
Section 12.06
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosisby Kaarina Kowalec on May 8, 2024
OBJECTIVE: Comorbid anxiety occurs often in MS and is associated with disability progression. Polygenic scores offer a possible means of anxiety risk prediction but often have not been validated outside the original discovery population. We aimed to investigate the association between the Generalized Anxiety Disorder 2-item scale polygenic score with anxiety in MS.
- Patient-reported outcomes in epilepsy: a case study exploring their usage and impactby Simona Lattanzi on May 8, 2024
CONCLUSIONS: Despite the heterogeneity in the actual collection of PRO, there was a uniform perception about their role to optimize the care of people with epilepsy.
- Negative affect instability predicts elevated depressive and generalized anxiety disorder symptoms even when negative affect intensity is controlled for: an ecological momentary assessment studyby Hedvig Sultson on May 8, 2024
INTRODUCTION: Mood and anxiety disorders are characterized by abnormal levels of positive affect (PA), negative affect (NA) and changes in how emotions unfold over time. To better prevent and treat those disorders, it is crucial to determine which kind of indices of emotion dynamics best predict elevated depressive and generalized anxiety symptoms.
- Treatment Condition as a Moderator and Change in Trait Mindfulness as a Mediator of a Brief Mindfulness Ecological Momentary Intervention for Generalized Anxiety Disorderby Nur Hani Zainal on May 7, 2024
No abstract